BiotechTube
Home/Foghorn Therapeutics/Carlos Costa
CC

Carlos Costa

Chief People Officer

Foghorn Therapeutics

Therapeutic Areas

Oncology

Foghorn Therapeutics Pipeline

DrugIndicationPhase
FHD-286Relapsed/Refractory Acute Myeloid Leukemia (AML)Phase 1
FHD-609Synovial SarcomaPhase 1
FHD-909Indication TBD (BRM-selective inhibitor)Phase 1

Leadership Team at Foghorn Therapeutics

AG
Adrian Gottschalk
President and Chief Executive Officer
SB
Steven Bellon
Chief Scientific Officer
DD
Danette Daniels
Vice President, Protein Degrader Platform
View full Foghorn Therapeutics profile